Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 14, 2006; 12(42): 6766-6770
Published online Nov 14, 2006. doi: 10.3748/wjg.v12.i42.6766
Published online Nov 14, 2006. doi: 10.3748/wjg.v12.i42.6766
Cell line | Dosage(mg/kg) | Body weight(mean ± SD, g) | Tumor weight(mean ± SD, g) | Tumor growthinhibition (%) |
SGC-7901 | ||||
0 | 22.12 ± 2.31 | 2.30 ± 0.67 | ||
25 | 21.62 ± 1.96 | 1.21 ± 0.61 | 30.49 | |
50 | 20.28 ± 2.95 | 0.75 ± 0.17 | 53.24 | |
100 | 18.05 ± 2.40 | 1.23 ± 0.43 | 65.98 | |
MKN-45 | ||||
0 | 22.72 ± 1.75 | 1.84 ± 0.72 | ||
25 | 21.62 ± 1.96 | 1.09 ± 0.81 | 40.76 | |
50 | 20.28 ± 2.95 | 0.71 ± 0.40 | 61.41 | |
100 | 18.75 ± 1.44 | 0.33 ± 0.49 | 82.07 |
- Citation: Liu J, Xu WF, Cui SX, Zhou Y, Yuan YX, Chen MH, Wang RH, Gai RY, Makuuchi M, Tang W, Qu XJ. Inhibition of human gastric carcinoma cell growth by atofluding derivative N3-o-toluyl-fluorouracil. World J Gastroenterol 2006; 12(42): 6766-6770
- URL: https://www.wjgnet.com/1007-9327/full/v12/i42/6766.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i42.6766